| |
|
|
|
|
Xuehai Tan, Ph.D., CEO
& President, Chairman of the board
Dr. Tan obtained his Ph.D. in Biochemistry from the
Medical College of Ohio in 1990. He then served as
a postdoctoral research fellow and later a research
assistant professor in the Biochemistry Department
of the University of Washington. In 1993, he became
a scientist at Baxter Biotech. In 1995, Dr. Tan joined
the Johnson and Johnson Pharmaceutical Research Department
and served as a senior scientist. Subsequently, he
worked at Aurora Biosciences, one of the leading drug
screening companies in the world at the time, as a
senior scientist and project manager. Dr. Tan has
had more than ten years of experience in both academics
and the biotechnology industry. He is a leading expert
in assay development and high-throughput screening
and has made significant accomplishments in drug discovery
research.
Zhongli Zheng, Ph.D., Senior Vice President,
Business Development
Dr. Zheng received his Ph.D. in Organic Chemistry,
Yale University in 1989. He joined Biogen, Inc. in
1993 and severed as Senior Scientist and then Associate
Directors in drug discovery to oversee small molecule
projects in two therapeutic areas: Fibrosis and Oncology.
Subsequently, Dr. Zheng worked as Vice President of
R&D Operations in NeoGenesis Pharmaceuticals,
Inc. to streamlined the operation of NeoGenesis drug
discovery engine. Dr. Zheng has over 16 years experience
in Biotech industry with both R & D management
and business development experiences.
Jingcai Chen, Ph.D., Vice President, Assay
Development
Dr. Chen received his Ph. D. in Immunology from the
Chinese Academy of Medical Sciences. In 1987, he worked
in the National Vaccine & Serum Institute (NVSI).
In 2002, he joined the Johnson & Johnson Pharmaceutical
Research and Development as a research scientist.
Before joining HD Biosciences, he worked as Vice President
of Suzhou Xinbao Pharmaceutical Co. Ltd. and was in
charge of project development and quality control.
Dr Chen has more than fifteen years of experience
in biotechnology and academic research, and has strong
background in G protein coupled receptor research.
Jian Wang, Ph.D., Director
Dr. Wang received his Ph.D. from the University of
Texas at Galveston before conducting his postdoctoral
research at the University of Iowa and the University
of Washington in the field of molecular pathology.
Currently, he is also a visiting professor and the
Executive Director of the Human Genomics Institute
of the Chinese Academy of the Sciences. He co-founded
BGI in 1998 and has been its chief executive since.
Dr. Wang has a strong background in academic research
and is highly experienced in the management of biotech
companies. |
|
|
|
|
